Phase 1b Study Of Docetaxel + PF 03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer

The purpose of this study is to determine the safety and tolerability of PF-03084014 in patients with metastatic or locally recurrent / advanced triple-negative breast cancer (mTNBC). PF-03084014 is a selective gamma secretase (GS) inhibitor with potential antitumor activity. In addition we hope to learn about the tumor killing effect that PR-03084014 may have when taken in combination with docetaxel. We would also like to see how long after treatment PF-03084014 remains in the body, and see what PF-03084014 taken in combination with docetaxel does to the body, for example, how it stimulates the body to fight cancer.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : PF-03084014
  • drug : PF-03084014
  • drug : Docetaxel
  • drug : Docetaxel
  • drug : PF-03084014

Phase: Phase 1

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Diagnosis of breast cancer with evidence of a) metastatic or b) locally recurrent/advanced disease.

External Links

Explore related trials

Contact information

Primary Contact:

Karen Lau 650-723-0658

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: